Trimethoprim-Sulfamethoxazole ( DrugBank: Trimethoprim, Sulfamethoxazole )

3 diseases
告示番号疾患名（ページ内リンク）臨床試験数
49全身性エリテマトーデス1
61自己免疫性溶血性貧血1
299嚢胞性線維症1

49. 全身性エリテマトーデス

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03042260
(ClinicalTrials.gov)		March 1, 201710/1/2017Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus ErythematousProphylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled TrialLupus Erythematosus, SystemicDrug: Trimethoprim-Sulfamethoxazole;Drug: Placebo Oral TabletInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranNational Council of Science and Technology, MexicoRecruiting18 YearsN/AAll310Phase 4Mexico

61. 自己免疫性溶血性貧血

臨床試験数 : 146 /  薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2021-002844-66-IT
(EUCTR)		23/11/202123/09/2021Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic AnemiaA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia - NA Primary Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: Parsaclisib (1 mg)
Product Code: [INCB050465]
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: Parsaclisib (2.5 mg)
Product Code: [INCB050465]
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: trimethoprim-sulfamethoxazole
Product Code: [trimethoprim-sulfamethoxazole]
INN or Proposed INN: TRIMETOPRIM + SULFAMETOSSAZOLO *
Product Name: pentamidine
Product Code: [pentamidine]
INN or Proposed INN: PENTAMIDINA ISETIONATO
Product Name: atovaquone
Product Code: [atovaquone]
INN or Proposed INN: ATOVAQUONE		INCYTE CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		100Phase 3United States;Spain;Ukraine;Austria;Israel;United Kingdom;Italy;France;Canada;Belgium;Poland;Germany;Netherlands;Japan

299. 嚢胞性線維症

臨床試験数 : 1,695 /  薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2013-000219-25-IT
(EUCTR)		18/07/201312/04/2018MRSA study.Early eradication of S. Aureus (MRSA) in patients with cystic fibrosis: a randomized multicenter study. Patients affected by cystic fibrosis and who present an initial infection of MRSA.;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]Product Name: Rifampin
INN or Proposed INN: RIFAMPICIN
Product Name: Trimethoprim-sulfamethoxazole
INN or Proposed INN: SULFAMETHOXAZOLE
Other descriptive name: TRIMETHOPRIM
Product Name: minocycline
Other descriptive name: MINOCYCLINE HYDROCHLORIDE		AOU MeyerNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		100Phase 3Italy